ArticleChemistry & biodiversity2026
Exploring the Active Substances and Mechanism of Physalis Calyx seu Fructus Against Inflammation-related Respiratory Diseases via Integrating Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry, Network Pharmacological Analysis, and Experimental Verification.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Salicifoliosides A and B: A Pair of Furan Glycoside Isomers From Chimonanthus salicifolius and Their Modulation of the Functions of Caco-2 Cells.Chemistry & biodiversity · 2026Article
- Diterpenoids from the genus Croton and their biological activities.Archives of pharmacal research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Physalis Calyx seu Fructus (PCF) is frequently prescribed for treating inflammation-related respiratory diseases in traditional Chinese medicine. The aim of the study is to identify the active partitions of PCF against inflammation-related respiratory diseases and explore their therapeutic effects and mechanisms. In the present study, two active partitions, 50-EFP-2 and 70-EFP, were obtained through anti-inflammatory bioactivity-guided enrichment of macroporous resin. These two partitions at 10 mg/kg potently alleviated lipopolysaccharide (LPS)-stimulated acute lung inflammation (ALI) and ovalbumin (OVA)-induced asthma in mice. Phytochemical investigation was performed using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) and high-performance LC (HPLC), and indicated that withanolides are the predominant constituents of these two partitions. Moreover, their potential targets were predicted by network pharmacological analysis, which showed that withanolides in PCF mainly attenuated ALI and asthma by regulating nuclear factor-κB (NF-κB) to inhibit inflammatory response. 50-EFP-2 and 70-EFP inhibited inflammation and oxidative stress by regulating NF-κB and nuclear factor erythroid 2-related factor 2 (Nrf2), both in vivo and in vitro. Collectively, two partitions rich in withanolides were discovered from PCF, which potently alleviated ALI and asthma by regulating Nrf2 and NF-κB pathways. These findings provide the foundation for discovering withanolide-type leading compounds and developing novel therapeutics against inflammation-related respiratory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.